Hebert AA - Search Results

1

Ozenoxacin: a review of preclinical and clinical efficacy.

Vila J, Hebert AA, Torrelo A, López Y, Tato M, García-Castillo M, Cantón R. Vila J, et al. Among authors: hebert aa. Expert Rev Anti Infect Ther. 2019 Mar;17(3):159-168. doi: 10.1080/14787210.2019.1573671. Epub 2019 Feb 11. Expert Rev Anti Infect Ther. 2019. PMID: 30686133 Review.

2

Topical Antibacterial Agent for Treatment of Adult and Pediatric Patients With Impetigo: Pooled Analysis of Phase 3 Clinical Trials.

Hebert AA, Albareda N, Rosen T, Torrelo A, Grimalt R, Rosenberg N, Zsolt I, Masramon X. Hebert AA, et al. J Drugs Dermatol. 2018 Oct 1;17(10):1051-1057. J Drugs Dermatol. 2018. PMID: 30365584 Clinical Trial.

3

Treatment of Impetigo and Antimicrobial Resistance.

Schachner LA, Lynde CW, Kircik LH, Torrelo A, Hohl D, Kwong P, Oza V, Andriessen A, Hebert AA. Schachner LA, et al. Among authors: hebert aa. J Drugs Dermatol. 2021 Apr 1;20(4):366-372. doi: 10.36849/JDD.2021.5795. J Drugs Dermatol. 2021. PMID: 33852242 Review.

4

Efficacy and Safety of Ozenoxacin Cream for Treatment of Adult and Pediatric Patients With Impetigo: A Randomized Clinical Trial.

Rosen T, Albareda N, Rosenberg N, Alonso FG, Roth S, Zsolt I, Hebert AA. Rosen T, et al. Among authors: hebert aa. JAMA Dermatol. 2018 Jul 1;154(7):806-813. doi: 10.1001/jamadermatol.2018.1103. JAMA Dermatol. 2018. PMID: 29898217 Free PMC article. Clinical Trial.

5

A comparative review of current topical antibiotics for impetigo.

Galindo E, Hebert AA. Galindo E, et al. Among authors: hebert aa. Expert Opin Drug Saf. 2021 Jun;20(6):677-683. doi: 10.1080/14740338.2021.1902502. Epub 2021 Apr 13. Expert Opin Drug Saf. 2021. PMID: 33726585

6

Pimecrolimus in atopic dermatitis: consensus on safety and the need to allow use in infants.

Luger T, Boguniewicz M, Carr W, Cork M, Deleuran M, Eichenfield L, Eigenmann P, Fölster-Holst R, Gelmetti C, Gollnick H, Hamelmann E, Hebert AA, Muraro A, Oranje AP, Paller AS, Paul C, Puig L, Ring J, Siegfried E, Spergel JM, Stingl G, Taieb A, Torrelo A, Werfel T, Wahn U. Luger T, et al. Among authors: hebert aa. Pediatr Allergy Immunol. 2015 Jun;26(4):306-15. doi: 10.1111/pai.12331. Epub 2015 Apr 13. Pediatr Allergy Immunol. 2015. PMID: 25557211 Free PMC article. Review.

7

Safety and efficacy profile of ozenoxacin 1% cream in pediatric patients with impetigo.

Hebert AA, Rosen T, Albareda López N, Zsolt I, Masramon X. Hebert AA, et al. Int J Womens Dermatol. 2019 Nov 14;6(2):109-115. doi: 10.1016/j.ijwd.2019.10.008. eCollection 2020 Mar. Int J Womens Dermatol. 2019. PMID: 32258344 Free PMC article.

8

Bacterial resistance and impetigo treatment trends: a review.

Bangert S, Levy M, Hebert AA. Bangert S, et al. Among authors: hebert aa. Pediatr Dermatol. 2012 May-Jun;29(3):243-8. doi: 10.1111/j.1525-1470.2011.01700.x. Epub 2012 Feb 3. Pediatr Dermatol. 2012. PMID: 22299710 Review.

9

Comparative safety and efficacy of clarithromycin and cefadroxil suspensions in the treatment of mild to moderate skin and skin structure infections in children.

Hebert AA, Still JG, Reuman PD. Hebert AA, et al. Pediatr Infect Dis J. 1993 Dec;12(12 Suppl 3):S112-7. doi: 10.1097/00006454-199312003-00004. Pediatr Infect Dis J. 1993. PMID: 8295811 Clinical Trial.

10

Safety and efficacy of desonide hydrogel 0.05% in pediatric subjects with atopic dermatitis.

Hebert AA, Cook-Bolden FE, Basu S, Calvarese B, Trancik RJ; Desonide Hydrogel Study Group. Hebert AA, et al. J Drugs Dermatol. 2007 Feb;6(2):175-81. J Drugs Dermatol. 2007. PMID: 17373176 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

223 results

Search Page